Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Earnings Report 5.284 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.894 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.682 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Eli Lilly is experiencing explosive growth thanks ... Mounjaro and Zepbound are still on pace for a record performance in Q4 -- despite falling short of Wall Street's aggressive targets.

On Jan. 14, Eli Lilly released its guidance for the fourth ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE ... are still on pace for a record performance in Q4 -- despite falling short of Wall Street's aggressive ...